Publications
Detailed Information
Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Juwon | - |
dc.contributor.author | Kim, Kyung Im | - |
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Won, Nam-Hee | - |
dc.contributor.author | Lee, Dong Soon | - |
dc.contributor.author | Ahn, Kwang-Sung | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Kim, Byoung Kook | - |
dc.contributor.author | Oh, Jung Mi | - |
dc.date.accessioned | 2012-06-25T04:15:34Z | - |
dc.date.available | 2012-06-25T04:15:34Z | - |
dc.date.issued | 2010-09 | - |
dc.identifier.citation | EXPERIMENTAL HEMATOLOGY; Vol.38 9; 773-781 | ko_KR |
dc.identifier.issn | 0301-472X | - |
dc.identifier.uri | https://hdl.handle.net/10371/77373 | - |
dc.description.abstract | Objective. In this study, we report a newly established chronic myeloid leukemia (CML) cell line, SNUCML-02, which is resistant to imatinib and describe its biological characteristics. Materials and Methods. Mononuclear cells were obtained from the bone marrow of a CIVIL patient in blast crisis and were cultured in Dulbecco`s modified Eagle`s medium/F12 containing 20% fetal bovine serum. After 2 months of primary culture, these cells were injected into nonobese diabetic/severe combined immune-deficient mice via tail vein. Eight weeks alter injection, mice were sacrificed and ex vivo culture was performed from the bone marrow cells isolated from the mice. The established cell line was named as SNUCML-02 and the biological features were characterized by cytogenetic analysis, fluorescence in situ hybridization, reverse transcriptase polymerase chain reaction. sequencing analysis, cell proliferation assay. and Western blot analysis. Results. Cytogenetic studies using conventional G-banding and fluorescent in situ hybridization of SNUCML-02 demonstrated classical Philadelphia chromosome, (9;22)(q34;q11.2), and other abnormalities, such as add(11)(q23), +19 and +der(9;22). SNUCML-02 has the same BCR-ABL, fusion transcript as was seen in K562 cells, but has no mutations in the ABL kinase domain. SNUCML-02 was more resistant to imatinib (STI571, Gleevec, Glivec) than other CML cell lines (K562. Kc122, and BV173). SNUCML-02 has constitutive activation of extracellular signal-regulated kinase phosphorylation. In addition, interleukin-3 induced phosphorylation and constitutively enhanced extracellular signal-regulated kinase phosphorylation was not inhibited by imatinib in SNUCML-02. Conclusion. SNUCML-02 is a new established cell line with a relatively high level of resistance to imatinib, which is useful for investigating the pathogenesis of CML progression, and will be useful in developing optimal therapeutic strategies for this ailment. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER SCIENCE INC | ko_KR |
dc.title | Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 박주원 | - |
dc.contributor.AlternativeAuthor | 김경임 | - |
dc.contributor.AlternativeAuthor | 고영일 | - |
dc.contributor.AlternativeAuthor | 원남희 | - |
dc.contributor.AlternativeAuthor | 오정미 | - |
dc.contributor.AlternativeAuthor | 이동순 | - |
dc.contributor.AlternativeAuthor | 김병국 | - |
dc.contributor.AlternativeAuthor | 안광성 | - |
dc.contributor.AlternativeAuthor | 윤성수 | - |
dc.identifier.doi | 10.1016/j.exphem.2010.04.012 | - |
dc.citation.journaltitle | EXPERIMENTAL HEMATOLOGY | - |
dc.description.citedreference | Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567 | - |
dc.description.citedreference | Donato NJ, 2004, CANCER RES, V64, P672 | - |
dc.description.citedreference | Branford S, 2003, BLOOD, V102, P276, DOI 10.1182/bloo-2002-09-2896 | - |
dc.description.citedreference | Donato NJ, 2003, BLOOD, V101, P690 | - |
dc.description.citedreference | Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081 | - |
dc.description.citedreference | Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741 | - |
dc.description.citedreference | Campbell LJ, 2002, CANCER GENET CYTOGEN, V139, P30 | - |
dc.description.citedreference | Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678 | - |
dc.description.citedreference | Gorre ME, 2002, CURR OPIN HEMATOL, V9, P303 | - |
dc.description.citedreference | Buchdunger E, 2001, BBA-REV CANCER, V1551, pM11 | - |
dc.description.citedreference | Laurent E, 2001, CANCER RES, V61, P2343 | - |
dc.description.citedreference | Thiesing JT, 2000, BLOOD, V96, P3195 | - |
dc.description.citedreference | Faderl S, 1999, NEW ENGL J MED, V341, P164 | - |
dc.description.citedreference | Sawyers CL, 1999, NEW ENGL J MED, V340, P1330 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.